IP2Revenues

IP2Revenues is a life sciences venture creation firm that specializes in identifying, acquiring, and commercializing high-value intellectual property. The company employs a lean, virtual business model to transform early-stage therapeutic assets into clinical-stage biotechnology companies, focusing primarily on areas with significant unmet medical needs such as virology and neurology. IP2Revenues is best known for founding Antios Therapeutics, which advanced the Hepatitis B candidate ATI-2173 into Phase 2 trials, and Engage Therapeutics, which was acquired by UCB for its Phase 3 epilepsy treatment. By leveraging a network of industry experts and strategic partnerships, IP2Revenues streamlines the drug development process from IP acquisition through to clinical proof-of-concept.